Rova T Crash And Burn

Quote






Indeed not a peep out of Gonzo or Chase. RovaT is just the tip of the iceberg. Dark secrets lurk in Abbvie pipeline that are coming to a head one by one. SELL NOW ....Game over, but unfortunately Rick still wins after banking $40M.
 






anonymous said:
Indeed not a peep out of Gonzo or Chase. RovaT is just the tip of the iceberg. Dark secrets lurk in Abbvie pipeline that are coming to a head one by one. SELL NOW ....Game over, but unfortunately Rick still wins after banking $40M.
Click to expand...

game. set..match..yes its over...just placed market sell order for all my ABBV
 






anonymous said:
Rova T is DOA
The results shown in the presentation were even worse than we had feared, and although AbbVie’s stock sold off much more than the value of Rova- T after the announcement, we can’t help but regard the ongoing trials as largely fruitless exercises. Furthermore, the toxicity signal from the trial, along with the relatively marginal efficacy signal, justifies the complete elimination of all revenue associated with Rova-T from our company forecast and valuation for AbbVie. There was a lot to dislike about the data, he says, including the high 34% discontinuation rate in the study; “49 or these 116 premature discontinuations were due to progressive disease, with the others being due to adverse events or other undisclosed reasons.”For the primary endpoint over response rate, measured by change in the target lesion, of the 301 evaluable patients (presumably the other 38 patients were deceased or lost to follow up), the investigator-measured response rate was 18%, increasing modestly to 19.7% in the DLL3 high group. As measured by the independent review board, the response rate fell to 12.4% for the combined population, and 14.3% in the DLL3-high patients. And serious adverse events in the drug group ran high. Ultimately it seems unlikely in our view that Rova-T, or perhaps any variant of DLL3 antibody-drug conjugate medicine, will come to market, at least while the profile looks the way it did in TRINITY.
Porges conclusion: The drug and the class look dead on arrival at ASCO.
Click to expand...


Haven't seen anything official published yet. Still optimistic about Rova-T's future.
 






























anonymous said:
Post a current news story, I'd be interested because I can't find one.
Click to expand...

Here's two chief. They're harder to find and always buried under pro Abbvie stories. Large hedgefund and institutional holders of ABBV manipulate google and many websites along with twitter and facebook as to what appears to you. It's Pharma's Fake News and every Pharma company has it done either for or against them.

https://seekingalpha.com/article/4179660-thoughts-abbvies-rova-t-implosion

https://endpts.com/asco18-abbvie-co...t-its-6b-megablockbuster-rova-t-is-worthless/
 






anonymous said:
Here's two chief. They're harder to find and always buried under pro Abbvie stories. Large hedgefund and institutional holders of ABBV manipulate google and many websites along with twitter and facebook as to what appears to you. It's Pharma's Fake News and every Pharma company has it done either for or against them.

https://seekingalpha.com/article/4179660-thoughts-abbvies-rova-t-implosion

https://endpts.com/asco18-abbvie-co...t-its-6b-megablockbuster-rova-t-is-worthless/
Click to expand...
I refuse to believe this propaganda !! These are links to fake news !! I HAVE FULL FAITH IN RICKY !!!!!!!!
 






anonymous said:
Here's two chief. They're harder to find and always buried under pro Abbvie stories. Large hedgefund and institutional holders of ABBV manipulate google and many websites along with twitter and facebook as to what appears to you. It's Pharma's Fake News and every Pharma company has it done either for or against them.

https://seekingalpha.com/article/4179660-thoughts-abbvies-rova-t-implosion

https://endpts.com/asco18-abbvie-co...t-its-6b-megablockbuster-rova-t-is-worthless/
Click to expand...

Interesting articles, one person's opinion. I didn't read that Abbvie has officially scrapped Rova T though, just that the results weren't as good as expected.
 






anonymous said:
Interesting articles, one person's opinion. I didn't read that Abbvie has officially scrapped Rova T though, just that the results weren't as good as expected.
Click to expand...
FYI .That Lowe guy has been bashing RG for some time ..shall we say he's a bit biased?? LMAO!!!!

rRova T will do fine.don't believe that hateful culprit!!!
 












anonymous said:
Interesting articles, one person's opinion. I didn't read that Abbvie has officially scrapped Rova T though, just that the results weren't as good as expected.
Click to expand...

Actually its (2) persons opinion Lowe and Porges. Now its spreading like wildfire and many more analysts are realizing Rova T was a bust. The steady stock decline verifies this. Nobody said AbbVie scrapped it. How embarrassing is the fact Rick Blew $5.8 BILLION on Stemcentryx who sold Rick a lemon. This is where lack of a College degree is evident. BOD NEEDS TO FIRE RICK RIGHT NOW
 












I agree with the suggestion that Rova T is crashing and burning. The clinical trial data seems unlikely to be upended by new data set. I would look for heads to roll, but not yet. This transaction was all Gonzalez, Severino and Goesbruch. Several members of Rick's LT told their staff they had reservations about the technology. In any case, because Rick is involved, he will see if they can keep coasting on Humira price increases in the US before taking any action against Severino or Goesbruch. It is the C-Suite's solution to every business problem.
 






Below is an example of fake pay for play news. Motley, Fierce Pharma Ect. ALL play the game. Where the Hell in the business world, is failing sales considered "Fantastic News"? These are projections for six years from now and the best scenario is guessed at. It wont happen as described. The Street agrees
AbbVie Inc
NYSE: ABBV
$97.94 USD DOWN −0.97 (0.98%)


Humira's Sales Will Decline -- and It's Fantastic News for AbbVie
Even with falling sales, Humira should still rank as the top-selling drug in the world in 2024.

Keith Speights
(TMFFishBiz)
Jun 13, 2018 at 6:01AM

Can bad news be good news? For AbbVie (NYSE:ABBV), it can.

The company's top-selling drug, Humira, will begin to face biosimilar competition in Europe later this year. In early 2023, biosimilars to Humira will hit the U.S. market. There's no doubt that sales for the drug will decline over the next few years. That's the bad news.

But it's also good news for AbbVie. How? The rate of decline isn't projected to be very great, according to a report recently published by market research firm EvaluatePharma.

Sales for Humira are expected to decrease by 3% annually through 2024. As a result, EvaluatePharma thinks Humira will still rank as the No. 1 best-selling drug in the world seven years from now, despite lower revenue. That's good -- even fantastic -- news for AbbVie.


Humira of the future
In 2017, AbbVie reported Humira sales of $18.4 billion. The drug generated 65% of the company's total revenue. Humira claimed a market share of 34% last year in the global anti-rheumatic products market, according to EvaluatePharma.

Fast-forward to 2024. EvaluatePharma projects that Humira's total sales will drop to $15.2 billion. And that figure includes the portion of revenue belonging to Esai, AbbVie's partner in Japan. Humira's market share is expected to fall to less than 27%.

Still, Humira should be able to easily hold on to the No. 1 spot among the best-selling drugs in the world. Merck's Keytruda is projected to be a distant second, with estimated sales in 2024 of $12.7 billion.

The big reason Humira will maintain its position at the top is the U.S. market. U.S. sales of the drug are projected to be around $12.2 billion in 2024. That's not much lower than Humira's 2017 U.S. sales of nearly $12.4 billion. Will Amgen's (NASDAQ:AMGN) biosimilar Amjevita, which will go on sale in the U.S. effective Jan. 31, 2023, really make that small of a dent in Humira's sales? Not really. The impact will be greater than the 2024 projections indicate.

AbbVie expects U.S. sales of Humira will increase over the next few years. The company predicts that total sales of the drug will approach $21 billion by 2020. This means sales for Humira will be like an accordion -- expanding then contracting.

Buying time
These projections from EvaluatePharma confirm how good the deal with Amgen made last September really was for AbbVie. The company was able to do exactly what it wanted: Buy time.

Upadacitinib provides a great example of what this additional time for Humira without U.S. biosimilar competition gives AbbVie. The drug could win FDA approval for treating rheumatoid arthritis in 2019. EvaluatePharma projects that upadacitinib will be the No. 5 best-selling anti-rheumatic product in the world by 2024, with sales of nearly $2.6 billion. That amount by itself makes up a big chunk of the gap in annual Humira revenue in 2024 compared to 2017.

But AbbVie also has another successor to Humira that could launch next year. In April, the company submitted for FDA approval of risankizumab in treating psoriasis. The drug is also being evaluated in a phase 3 study for the treatment of Crohn's disease. EvaluatePharma projects that risankizumab could generate annual revenue of $2.1 billion by 2024.

The Amgen deal also bought time for AbbVie's existing products to ramp up sales considerably. Hepatitis C drug Mayvryet is expected to generate annual revenue of nearly $2.9 billion by 2024. Cancer drug Venclexta could rake in $2.8 billion by 2024, although AbbVie will share some of that revenue with its partner, Roche.

AbbVie's biggest-selling drug other than Humira, Imbruvica, should also enjoy strong momentum. EvaluatePharma thinks Imbruvica will be the No. 4 cancer drug in the world by 2024, with sales topping $9.5 billion. However, that total includes revenue made by AbbVie and Johnson & Johnson.
 
























Top Bottom
Back
Quote